ORC ID , Yu-Bao Lu2 ORC ID , Xiao-Lan Huang3, Yong-Feng Lao4, Lu Zhang4, Jun Yang4, Mei Shi4, Hai-Long Ma4, Ya-Wen Pan5, Yi-Nian Zhang MD, PhD 5">
  • Users Online: 1350
  • Home
  • Print this page
  • Email this page
REVIEW
Year : 2022  |  Volume : 17  |  Issue : 8  |  Page : 1711-1716

Myeloperoxidase: a new target for the treatment of stroke?


1 The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province; Xiangya Hospital, Central South University, Changsha, Hunan Province, China
2 The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province; Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China
3 University of Chinese Academy of Sciences, Beijing, China
4 The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
5 The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China

Correspondence Address:
Ya-Wen Pan
The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province
China
Yi-Nian Zhang
The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province
China
Login to access the Email id

Source of Support: This work was supported by the National Natural Science Foundation of China, No. 81771297 (to YNZ); CuiYing Scientific and Technological Innovation Program of Lanzhou University Second Hospital of China, No. CY2017-MS04 (to YNZ); Hui-Chun Chin and Tsung-Dao Lee Chinese Undergraduate Research Endowment of China, No. LZU-JZH2224 (to YCW); National Innovation and Entrepreneurship Training Program for Undergraduate of China, No. 201910730212 (to YCW); and CuiYing Scientific Training Program for Undergraduates of Lanzhou University Second Hospital of China, No. CYXZ2019-06 (to YCW), Conflict of Interest: None


DOI: 10.4103/1673-5374.332130

Rights and Permissions

Myeloperoxidase is an important inflammatory factor in the myeloid system, primarily expressed in neutrophils and microglia. Myeloperoxidase and its active products participate in the occurrence and development of hemorrhagic and ischemic stroke, including damage to the blood-brain barrier and brain. As a specific inflammatory marker, myeloperoxidase can be used in the evaluation of vascular disease occurrence and development in stroke, and a large amount of experimental and clinical data has indicated that the inhibition or lack of myeloperoxidase has positive impacts on stroke prognosis. Many studies have also shown that there is a correlation between the overexpression of myeloperoxidase and the risk of stroke. The occurrence of stroke not only refers to the first occurrence but also includes recurrence. Therefore, myeloperoxidase is significant for the clinical evaluation and prognosis of stroke. This paper reviews the potential role played by myeloperoxidase in the development of vascular injury and secondary brain injury after stroke and explores the effects of inhibiting myeloperoxidase on stroke prognosis. This paper also analyzes the significance of myeloperoxidase etiology in the occurrence and development of stroke and discusses whether myeloperoxidase can be used as a target for the treatment and prediction of stroke.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed176    
    Printed0    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal